1.36
price down icon5.56%   -0.08
after-market Handel nachbörslich: 1.28 -0.08 -5.88%
loading

Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten

pulisher
Apr 24, 2025

Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

How to interpret Tiziana Life Sciences Ltd (TLSA)’s stock chart patterns - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Tiziana Life Sciences Ltd: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com

Apr 24, 2025
pulisher
Apr 23, 2025

Small cap wrap: Tiziana Life Sciences, Excellon Resources, Lancaster Resources... - Proactive Investors

Apr 23, 2025
pulisher
Apr 23, 2025

Tiziana Life Sciences Announces University of Massachusetts Starts Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Breakthrough MS Treatment Trial: UMass Joins Harvard, Yale, Johns Hopkins Testing Home-Use Nasal Drug - Stock Titan

Apr 23, 2025
pulisher
Apr 23, 2025

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2… - Informazione.it

Apr 23, 2025
pulisher
Apr 23, 2025

Tiziana Life Sciences announces patient dosing in Phase 2 MS trial - Proactive financial news

Apr 23, 2025
pulisher
Apr 08, 2025

Multiple sclerosis Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025
pulisher
Apr 02, 2025

TLSATiziana Life Sciences Ltd Com Latest Stock News & Market Updates - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Small cap wrap: Zero Candida, Midnight Sun Mining, Tiziana Life Sciences, Trust Stamp... - Proactive financial news

Apr 02, 2025
pulisher
Apr 02, 2025

Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins - Proactive financial news

Apr 02, 2025
pulisher
Apr 02, 2025

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Major Breakthrough: Johns Hopkins Launches Novel Nasal Treatment in Phase 2 MS Trial - Stock Titan

Apr 02, 2025
pulisher
Mar 26, 2025

Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS - Proactive financial news

Mar 26, 2025
pulisher
Mar 25, 2025

Small cap wrap: Northern Superior Resources, Tiziana Life Sciences, Alternus Clean Energy... - Proactive Investors

Mar 25, 2025
pulisher
Mar 25, 2025

Multiple sclerosis Clinical Trials and Studies 2025: EMA, PDMA, - openPR

Mar 25, 2025
pulisher
Mar 25, 2025

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Yale Launches Groundbreaking Intranasal MS Treatment Trial: Tiziana's Innovation in Focus - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 MillionSEC Filing -March 24, 2025 at 05:22 pm EDT - Marketscreener.com

Mar 24, 2025
pulisher
Mar 17, 2025

Tiziana Life Sciences CEO to present at 37th Annual ROTH Conference - Proactive Investors UK

Mar 17, 2025
pulisher
Mar 17, 2025

Tiziana Life Sciences to Present at the 37th Annual Roth Conference - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Tiziana Life Sciences Reveals Growth Strategy at Major ROTH ConferenceKey Updates Expected - StockTitan

Mar 17, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule - The Manila Times

Mar 14, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Requirements - Nasdaq

Mar 14, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Regains Compliance With Nasdaq Listing Minimum Bid Price Rule - MENAFN.COM

Mar 14, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Dodges Delisting: How Company Saved Its Nasdaq Status - Stock Titan

Mar 14, 2025
pulisher
Mar 13, 2025

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St

Mar 13, 2025
pulisher
Mar 10, 2025

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease - Informazione.it

Mar 10, 2025
pulisher
Mar 10, 2025

Can Tiziana's Foralumab Enable Breakthroughs In Neuroinflammatory And Neurodegenerative Diseases? - RTTNews

Mar 10, 2025
pulisher
Mar 07, 2025

Tiziana Life Sciences stock soars to 52-week high of $1.75 - Investing.com

Mar 07, 2025
pulisher
Mar 06, 2025

Democrat-led states join legal fight over Trump's mass firings of federal workers -March 06, 2025 at 10:38 pm EST - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) Stock Hits Multi-Month High After Filing a Key IND with the FDA - DRP Journal

Mar 06, 2025
pulisher
Mar 05, 2025

Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment - Seeking Alpha

Mar 05, 2025
pulisher
Mar 04, 2025

Sector Update: Health Care -March 04, 2025 at 03:39 pm EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana submits FDA investigational new drug application - Proactive Investors UK

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Files New Drug Application for ALS Drug Candidate -March 04, 2025 at 09:03 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Advances ALS Treatment with FDA IND Submission - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Could This Intranasal Therapy Change ALS Treatment? Tiziana Seeks FDA Approval - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short Interest - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN

Mar 03, 2025
pulisher
Mar 02, 2025

Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 02, 2025
pulisher
Mar 01, 2025

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Mar 01, 2025
pulisher
Feb 27, 2025

Tiziana stock jumps 12% on TBI drug study publication - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Tiziana Life Sciences' lead candidate demonstrates favorable safety profile and clinical response - Proactive Investors UK

Feb 27, 2025
pulisher
Feb 27, 2025

Market movers: Ideal Power, Tiziana Life Sciences, Medicus Pharma... - Proactive financial news

Feb 27, 2025
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):